Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 14/20 | 1.00 |
| ▸ | TGM2 | P21980 | 4/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29253561 | 0.82 | CES1 (0.69) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL7048273 | 0.81 | CES1 (0.67) | CES1TGM2PDE7A | |
| SCHEMBL7048275 | 0.81 | CES1 (0.67) | CES1TGM2PDE7A | |
| SCHEMBL29446052 | 0.80 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL2496190 | 0.80 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL19260393 | 0.80 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL5738366 | 0.80 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL6177499 | 0.80 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL2372330 | 0.80 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL31103242 | 0.80 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479765-B2 | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10189788-B2 | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20190002409-A1 | SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-03 | — | — | US | disclosed |
| US-10117864-B2 | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| CN-105330666-B | Tryptamines ketone derivatives, synthetic method and its pharmaceutical usage | 西北大学 | 2018-10-30 | — | — | CN | disclosed |
| US-20180036300-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20170260140-A1 | SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Bayer Pharma Aktiengesekkschaft (DE) | 2017-09-14 | — | — | US | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-105330666-A | Novel tryptanthrin derivative, synthetic method and medicinal application thereof | UNIV NORTHWESTERN | 2016-02-17 | — | — | CN | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| US-5597922-A | Glycine receptor antagonist pharmacophore | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| WO-1996004288-A1 | GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
| US-4489003-A | ANTICONVULSANTS, TRANQUILLIZERS | HOFFMANN-LA ROCHE INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0002624-B1 | 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-14 | — | — | EP | disclosed |
| EP-0002624-A1 | 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-27 | — | — | EP | disclosed |
| US-4146718-A | BLOOD PLATELET ANTIAGGREGATIVE AGENT | BRISTOL-MYERS COMPANY (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479765-B2 | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | AADAC, NFKBIA, NOD2 | CES1 289/4885TGM2 566/4885PDE7A 1008/4885 |
| US-20170260140-A1 | SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS | AADAC, NFKBIA, NOD2 | CES1 289/4885TGM2 566/4885PDE7A 1008/4885 |
| US-20190002409-A1 | SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS | AADAC, NFKBIA, NOD2 | CES1 289/4885TGM2 566/4885PDE7A 1008/4885 |
| US-10117864-B2 | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | AADAC, BRD4, GOT2 | CES1 286/4885TGM2 638/4885PDE7A 1827/4885 |
| US-20180036300-A1 | SUBSTITUTED N-BICYCLO-2-ARYL-QUINOLIN-4-CARBOXAMIDES AND USE THEREOF | AADAC, BRD4, GOT2 | CES1 286/4885TGM2 638/4885PDE7A 1827/4885 |
| US-10189788-B2 | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents | AADAC, NFKBIA, NOD2 | CES1 289/4885TGM2 566/4885PDE7A 1008/4885 |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | CES1 272/4885TGM2 802/4885PDE7A 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.